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CASE REPORT 
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous 
Pemphigoid in Malta: A case report and clinical series 
Monique Cachia, Stephanie Pullicino, Alexandra Betts, Susan Aquilina
Bullous pemphigoid (BP) is an autoimmune blistering disease 
associated with a number of predisposing factors including age, 
neurological disease, diabetes mellitus and drugs. Over the past few 
years, dipeptidyl peptidase-4 inhibitors (DPP4-Is), referred to as 
gliptins, have been increasingly associated with the development of 
this blistering disease.  
Locally, since the introduction of gliptins into the national formulary, 
we have noted a surge in the number of cases of presumed gliptin-
induced BP. We present a local case report, followed by a short case 
series which highlights the typical characteristics of patients with 
gliptin-induced BP and shows the surge in the number of local cases.  
Patients with drug-induced BP, as opposed to conventional BP, tend 
to respond quicker upon cessation of the culprit drug. Therefore 
physicians should be aware of this association and have a low 
threshold for investigating diabetics who present with unexplained 
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INTRODUCTION 
Bullous pemphigoid (BP) is a sub-epidermal 
blistering skin disease mediated by 
autoantibodies to hemidesmosome proteins 
BP180 and BP230, which are crucial for stable 
adhesions between the epidermis and dermis.1 
Risk factors associated with this disease 
include age, neurologic disease, diabetes 
mellitus and various drugs. Over 60 different 
drugs have been associated with BP in the 
literature. However, in a recent systematic 
review only aldosterone antagonists, 
dopaminergic drugs, anticholinergics and 
dipeptidyl peptidase-4 inhibitors (DPP4-Is), 
have been shown to be statistically associated 
with BP.2  
DPP4-Is, widely referred to as gliptins, are oral 
hypoglycaemic agents used in type 2 diabetes. 
They were first introduced into the market in 
2006 and since then there has been evidence 
to suggest an association between the use of 
DPP4-Is and development of BP.1,3  
We report a case of an elderly diabetic man 
with presumed gliptin-induced BP. Moreover, 
we report a surge in the number of cases of BP 
in diabetic patients at our outpatient clinic a 
few months following the introduction of 
DDP4-Is into the national formulary. 
CASE PRESENTATION 
An 85-year old male presented with a one-
month history of large, pruritic, tense bullae on 
the lower aspect of both legs. The patient’s 
medical history included type 2 diabetes, 
hypertension and ischaemic heart disease, for 
which he was on a number of drugs which 
included vildagliptin, metformin, gliclazide, 
perindopril, aspirin, simvastatin, isosorbide 
dinitrate and omeprazole. Amlodipine had 
been stopped a few weeks prior to 
presentation in view of worsening of lower 
limb oedema. 
On examination, oedematous legs with bullae 
and some excoriation marks were visible. 
Initially the differential diagnosis included 
bullae associated with lower limb oedema, 
bullous diabeticorum and bullous pemphigoid. 
The former diagnosis was favoured at the 
outset in view of the incidental worsening of 
the lower limb oedema and the fact that the 
bullae only affected the legs. Thus the patient 
was commenced on a loop diuretic.  
A few days later the patient re-presented to 
clinic, this time having new bullae on the 
forearms. A punch biopsy was taken from the 
forearm and this revealed a subepidermal 
blister. Direct immunofluorescence showed 
linear deposits of IgG and C3 in the basement 
membrane zone which was consistent with a 
diagnosis of BP. He was treated with 
clobetasol propionate ointment applied onto 
the blisters, nicotinamide 500mg t.i.d and 
doxycycline 500mg b.i.d. The bullae initially 
healed without formation of new blisters but 
the patient complained of persistent pruritus. 
Eight months from the initial presentation, the 
patient presented urgently to clinic 
complaining of worsening pruritus, erythema 
and desquamation (Figure 1). After ensuring 
compliance to current treatment of BP a 
review of other possible triggers was done. Of 
note, the patient was on vildagliptin for 
diabetes which was the most recent drug 
added to his list. This had been started two 
years prior to this presentation. Keeping in 
mind the association of BP with DPP4-Is, 
vildagliptin was omitted following liaison with 
his diabetologist for alternative management. 
In the meantime, topical clobetasol propionate 
ointment was continued. There was complete 
resolution of his symptoms within three 
months from discontinuing vildagliptin, 
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suggesting a final diagnosis of BP that was 
























Drug-induced BP very often has the same 
clinical and histological features as classical 
BP. In its established form patients typically 
present with pruritus and formation of bullae. 
However, in the pre-bullous phase, the clinical 
picture of BP may be misleading and may only 
include pruritus with possibly vague 
erythematous and urticated areas. In drug-
induced BP patients very often respond well 
after the drug is stopped and have little or no 
relapses while patients with classical BP tend 
to have a more chronic course and very often 
require long term systemic therapy. 
Nevertheless, a small cohort of patients with 
drug-induced Bullous Pemphigoid who initially 
respond to stopping the culprit drug later on 
develop classical BP. 
Our patient had many risk factors for BP 
including age, DM and was taking a statin, ACE-
I and DPP4-I, all of which have been associated. 
Initially he was thought to have classic BP. 
However, as the patient complained of 
persistent pruritus and worsening erythema 
despite systemic therapy, a thorough review of 
his drug history confirmed that the most 
123
Malta Medical Journal     Volume 33 Issue 01 2021           
recently added medication was Vildagliptin 
prompting us to a possible association. 
In classical BP, autoantibodies typically target 
specific portions of the hemidesmosomal 
proteins of the basement membrane, BP180 
and BP230, which are normally crucial for 
maintaining adhesion between the epidermis 
and dermis. In 85% of cases these antibodies 
target the non-collagenous region 16A 
(NC16A) of BP180 (collagen XVII). Antibodies 
to BP230 are also found but to a lesser extent.4 
In drug-induced BP, the antibody target is 
similarly BP180 but the portion targeted may 
be different.4 In DPP4I-associated BP, the 
gliptin is thought to alter the antigenicity of 
BP180 making it more amenable to attack by 
antibodies. In this case they tend to target the 
mid-portion of BP180 rather than the NC16A 
domain as in classical BP5. 
DPP4-Is are a relatively new class of drugs 
which have been introduced into the market in 
2006. These drugs are used to treat type 2 
diabetes mellitus and act by competitively 
inhibiting the enzyme DPP4 which is normally 
found in various organs including the skin. 
DPP4 normally inactivates glucagon like 
peptide (GLP-1) and glucose-dependant 
insulinotropic polypeptide (GIP). DPP4-Is thus 
prevent inactivation of these incretins thereby 
increasing insulin levels and inhibiting 
glucagon production.6 
The first licensed gliptin was sitagliptin in 2006 
and this was followed by vildagliptin, 
saxagliptin, linagliptin and alogliptin.7 Since 
their introduction into the market there have 
been various case-reports, case-control trials 
and pharmacovigilance database studies which 
have confirmed an association between the 
use of gliptins and the development of BP. 
Moreover, a systematic review and adjusted 
meta-analysis by Phan et al. has positively 
suggested a significant association between 
DPP4-I use and development of BP. The 
strongest association was found with 
vildagliptin while sitagliptin did not seem to be 
associated with development of BP.3  
Locally, the DPP4-I vildagliptin was introduced 
into the national formulary in April 2016. 
Between 2017 and 2019 we have seen a surge 
in bullous pemphigoid amongst the diabetic 
community with a good proportion of these 
patients taking gliptins. We therefore 
retrospectively analysed the data of patients 
presenting to the department of dermatology 
at Sir Paul Boffa Hospital between 2017 and 
2019 with a known diagnosis of gliptin-induced 
BP (Table 1). 
The above findings are similar to the published 
data on the subject, which confirm that 
patients developing gliptin-induced BP were 
more likely to be male and elderly. The latency 
period between drug initiation and the 
development of symptoms also appeared to 
be quite variable in our findings (6-28 months) 
when compared to various pharmacovigilance 
reports which report a mean latency period 
that can vary between 6 to 19 months.3 Clinical 
symptoms appeared to resolve in a number of 
weeks to months, and 13 out of the 15 patients 
have remained symptom-free. The gliptin 
associated in all but one of the cases was 
vildagliptin, which is the only DPP4-I in the 
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Table 1 Summary of data 
Number of Patients 15 (1 patient deceased) 
DPP-IV inhibitor 93% Vildagliptin (14/15) 
7% Linagliptin (1/15) 
Sex (M/F) 60% M (8/15) 
40% F (6/15) 
Average age (yrs) 76 (59-87) 
Latency period before onset of 
bullous pemphigoid (in months) 
Mean 14 months 
(range: 6-28 months) 
Symptoms Pruritus and bullae13/15 
Pruritus without bullae 2/15 
Treatment (topical vs oral vs other) Topical steroids alone: 6/15 
Oral agents added: 9/15 









Stopping the drug in conjunction with short 
term application of topical steroids is usually 
sufficient to treat DPP4I-associated BP. 
However, few cases have been reported 
where, due to a phenomenon referred to as 
‘epitope spreading’ after cessation of the drug 
and initial improvement, patients may then 
develop conventional BP.5 Two of our patients 
had initially responded to treatment and later 
started complaining of re-emerging 
symptoms, possibly due to development of 
classical BP. These have been started on 
systemic drugs.  
Locally, the numbers of cases of presumed 
gliptin-induced BP have been notably high 
when compared to the current literature.3 
Between 2017-2019 we had 15 patients 
presenting with this diagnosis with 11 of these 
patients presenting in the second half of 2018 
(Figure 2). These findings could be explained 
by the initiation of gliptins in a large cohort of 
diabetic patients once introduced into the 
formulary in 2016. The surge in 2018, could be 
explained by the long latency period and 
reflects the bulk of patients that were started. 
Moreover, some patients might have been 
misdiagnosed as gliptin-induced BP rather 
than classical BP due to the increasing 
awareness of this association. Confirmation of 
drug-induced BP can only be done upon re-
challenge of the drug, which is not ethically 
correct. 
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Figure 2 Bar graph showing the number of new cases presenting with a diagnosis of gliptin-















This case highlights the importance of keeping 
drugs in mind as potential culprits for skin 
disease. Many drugs may have a long latency 
period, so a thorough drug history including 
the time when the drugs were started is 
relevant. Physicians should be aware of the 
association between BP and DPP4-I and have a 
low threshold for investigating patients on 
gliptins who present with non-specific pruritus 
with or without the presence of bullae.
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